Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients

Infectious Disease Clinics of North America

Volumn 27, Issue 2, 2013, Pages 317-342

  Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allograft rejection; Cytomegalovirus; Graft failure; Nucleic acid testing; Polymerase chain reaction; Valganciclovir; Viral load

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; EVEROLIMUS; FOSCARNET; GANCICLOVIR; PLACEBO; RAPAMYCIN; VALACICLOVIR; VALGANCICLOVIR;

ANTIBODY DETECTION; BLOOD SAMPLING; BONE MARROW TOXICITY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FEVER; FLU LIKE SYNDROME; GENE MUTATION; GENOTYPE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; KIDNEY TRANSPLANTATION; LABORATORY DIAGNOSIS; LEUKOPENIA; LUNG TRANSPLANTATION; MALAISE; NEPHROTOXICITY; NEUROLOGIC DISEASE; NUCLEIC ACID ANALYSIS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIMARY INFECTION; RECIPIENT; REVIEW; RISK FACTOR; SEROLOGY; SEROPREVALENCE; SUPERINFECTION; SURVIVAL RATE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS CULTURE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; IMMUNOCOMPROMISED HOST; MOLECULAR DIAGNOSTIC TECHNIQUES; OPPORTUNISTIC INFECTIONS; POLYMERASE CHAIN REACTION; TRANSPLANTATION; TRANSPLANTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84878231546     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2013.02.005     Document Type: Review

References (120)

1. Beam E., Razonable R.R. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012, 14(6):633-641.
2. Bate S.L., Dollard S.C., Cannon M.J. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010, 50(11):1439-1447.
3. Cannon M.J., Schmid D.S., Hyde T.B. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010, 20(4):202-213.
4. Watkins R.R., Lemonovich T.L., Razonable R.R. Immune response to CMV in solid organ transplant recipients: current concepts and future directions. Expert Rev Clin Immunol 2012, 8(4):383-393.
5. Dunn H.S., Haney D.J., Ghanekar S.A., et al. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis 2002, 186(1):15-22.
6. Razonable R.R. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005, 62(8 Suppl 1):S7-S13.
7. Manuel O., Pang X.L., Humar A., et al. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009, 199(11):1621-1628.
8. Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them?. Enferm Infecc Microbiol Clin 2010, 28(1):1-5.
9. Arthurs S.K., Eid A.J., Deziel P.J., et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010, 24(3):341-348.
10. Arthurs S.K., Eid A.J., Pedersen R.A., et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007, 13(12):1703-1709.
11. Arthurs S.K., Eid A.J., Pedersen R.A., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008, 46(6):840-846.
12. Asberg A., Jardine A.G., Bignamini A.A., et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 2010, 10(8):1881-1888.
13. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001, 184(11):1461-1464.
14. Razonable R., Humar A. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2013, 13(Suppl 4):93-106.
15. Chou S.W. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986, 314(22):1418-1423.
16. Emery V.C., Hassan-Walker A.F., Burroughs A.K., et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002, 185(12):1723-1728.
17. Emery V.C., Manuel O., Asberg A., et al. Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. J Clin Virol 2012, 54(1):56-60.
18. Emery V.C., Sabin C.A., Cope A.V., et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355(9220):2032-2036.
19. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4(4):611-620.
20. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 1997, 350(9093):1729-1733.
21. Lowance D., Neumayer H.H., Legendre C.M., et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999, 340(19):1462-1470.
22. Humar A., Lebranchu Y., Vincenti F., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10(5):1228-1237.
23. Humar A., Limaye A.P., Blumberg E.A., et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010, 90(12):1427-1431.
24. Cummins N.W., Deziel P.J., Abraham R.S., et al. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 2009, 11(1):20-27.
25. Slifkin M., Tempesti P., Poutsiaka D.D., et al. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001, 33(7):E62-E68.
26. Razonable R.R., Burak K.W., van Cruijsen H., et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002, 35(8):974-981.
27. Humar A., Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6(2):262-274.
28. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34(8):1094-1097.
29. Eid A.J., Arthurs S.K., Deziel P.J., et al. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2010, 10(1):157-161.
30. Drage M., Reid A., Callaghan C.J., et al. Acute cytomegalovirus cholecystitis following renal transplantation. Am J Transplant 2009, 9(5):1249-1252.
31. Kini U., Nirmala V. Post-transplantation epididymitis associated with cytomegalovirus. Indian J Pathol Microbiol 1996, 39(2):151-153.
32. Eid A.J., Bakri S.J., Kijpittayarit S., et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008, 10(1):13-18.
33. Laifer S.A., Ehrlich G.D., Huff D.S., et al. Congenital cytomegalovirus infection in offspring of liver transplant recipients. Clin Infect Dis 1995, 20(1):52-55.
34. Munoz-Price L.S., Slifkin M., Ruthazer R., et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004, 39(9):1293-1299.
35. George M.J., Snydman D.R., Werner B.G., et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, Medimmune, Inc. Gaithersburg, Maryland. Am J Med 1997, 103(2):106-113.
36. Walker R.C., Marshall W.F., Strickler J.G., et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995, 20(5):1346-1353.
37. Antoine P., Olislagers V., Huygens A., et al. Functional exhaustion of CD4+ t lymphocytes during primary cytomegalovirus infection. J Immunol 2012, 189(5):2665-2672.
38. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004, 78(9):1390-1396.
39. Kliem V., Fricke L., Wollbrink T., et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008, 8(5):975-983.
40. Reischig T., Jindra P., Hes O., et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008, 8(1):69-77.
41. Helantera I., Lautenschlager I., Koskinen P. The risk of cytomegalovirus recurrence after kidney transplantation. Transpl Int 2011, 24(12):1170-1178.
42. Zamora M.R. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002, 21(8):841-849.
43. Potena L., Valantine H.A. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007, 20(4):425-431.
44. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004, 23(Suppl 5):S187-S193.
45. Asberg A., Humar A., Rollag H., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7(9):2106-2113.
46. Bosch W., Heckman M.G., Diehl N.N., et al. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011, 11(10):2181-2189.
47. Eid A.J., Razonable R.R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70(8):965-981.
48. Atabani S.F., Smith C., Atkinson C., et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012, 12(9):2457-2464.
49. Emery V.C., Cope A.V., Bowen E.F., et al. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190(2):177-182.
50. Portela D., Patel R., Larson-Keller J.J., et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995, 171(4):1014-1018.
51. Sarmiento J.M., Dockrell D.H., Schwab T.R., et al. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000, 14(2):136-138.
52. Brennan D.C., Legendre C., Patel D., et al. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011, 11(11):2453-2462.
53. Corona-Nakamura A.L., Monteon-Ramos F.J., Troyo-Sanroman R., et al. Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients. Transplant Proc 2009, 41(6):2412-2415.
54. Kijpittayarit S., Eid A.J., Brown R.A., et al. Relationship between toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007, 44(10):1315-1320.
55. Kang S.H., Abdel-Massih R.C., Brown R.A., et al. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012, 205(4):639-646.
56. de Rooij B.J., van der Beek M.T., van Hoek B., et al. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J Hepatol 2011, 55(4):800-807.
57. Kwakkel-van Erp J.M., Paantjens A.W., van Kessel D.A., et al. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol 2011, 165(3):410-416.
58. Humar A., Asberg A., Kumar D., et al. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009, 9(2):374-381.
59. Razonable R.R., Paya C.V., Smith T.F. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002, 40(3):746-752.
60. Florescu D.F., Mindru C., Chambers H.E., et al. Clostridium difficile and cytomegalovirus colitis co-infection: search for the hidden 'bug'. Transpl Infect Dis 2011, 13(4):411-415.
61. Arslan H., Inci E.K., Azap O.K., et al. Etiologic agents of diarrhea in solid organ recipients. Transpl Infect Dis 2007, 9(4):270-275.
62. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005, 5(5):1065-1070.
63. Boivin G., Goyette N., Farhan M., et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012, 53(3):208-213.
64. Eid A.J., Arthurs S.K., Deziel P.J., et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008, 22(2):162-170.
65. Limaye A.P., Corey L., Koelle D.M., et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000, 356(9230):645-649.
66. Limaye A.P., Raghu G., Koelle D.M., et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002, 185(1):20-27.
67. Lurain N.S., Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010, 23(4):689-712.
68. Caliendo A.M., St George K., Kao S.Y., et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000, 38(6):2122-2127.
69. Humar A., Gregson D., Caliendo A.M., et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999, 68(9):1305-1311.
70. Razonable R.R., Brown R.A., Wilson J., et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002, 73(6):968-973.
71. Hayden R.T., Yan X., Wick M.T., et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol 2012, 50(2):337-345.
72. Pang X.L., Fox J.D., Fenton J.M., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9(2):258-268.
73. Razonable R.R., Brown R.A., Espy M.J., et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001, 39(12):4472-4476.
74. Pang X.L., Chui L., Fenton J., et al. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol 2003, 41(7):3167-3174.
75. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006, 6(9):2134-2143.
76. Witzke O., Hauser I.A., Bartels M., et al. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation 2012, 93(1):61-68.
77. Kalil A.C., Levitsky J., Lyden E., et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005, 143(12):870-880.
78. Small L.N., Lau J., Snydman D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006, 43(7):869-880.
79. Boivin G., Goyette N., Rollag H., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14(5):697-704.
80. Myhre H.A., Haug Dorenberg D., Kristiansen K.I., et al. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011, 92(2):217-223.
81. Levitsky J., Singh N., Wagener M.M., et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008, 8(1):158-161.
82. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004, 4(4):644-649.
83. Lisboa L.F., Preiksaitis J.K., Humar A., et al. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011, 92(9):1063-1068.
84. Palmer S.M., Limaye A.P., Banks M., et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010, 152(12):761-769.
85. Humar A., Kumar D., Preiksaitis J., et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005, 5(6):1462-1468.
86. Zamora M.R., Nicolls M.R., Hodges T.N., et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004, 4(10):1635-1642.
87. Finlen Copeland C.A., Davis W.A., Snyder L.D., et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011, 30(9):990-996.
88. Wiita A.P., Roubinian N., Khan Y., et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012, 14(3):248-258.
89. Snydman D.R., Falagas M.E., Avery R., et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc 2001, 33(4):2571-2575.
90. Snydman D.R., Werner B.G., Dougherty N.N., et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993, 119(10):984-991.
91. Bonaros N., Mayer B., Schachner T., et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008, 22(1):89-97.
92. Hodson E.M., Jones C.A., Strippoli G.F., et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007, (2). CD005129.
93. Razonable R.R., van Cruijsen H., Brown R.A., et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003, 187(11):1801-1808.
94. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191(1):89-92.
95. Conti D.J., Freed B.M., Singh T.P., et al. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995, 130(11):1217-1221. [discussion: 21-2].
96. Hibberd P.L., Tolkoff-Rubin N.E., Conti D., et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995, 123(1):18-26.
97. Humar A., Kumar D., Boivin G., et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002, 186(6):829-833.
98. Sia I.G., Wilson J.A., Groettum C.M., et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000, 181(2):717-720.
99. Asberg A., Humar A., Jardine A.G., et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009, 9(5):1205-1213.
100. Lisboa L.F., Asberg A., Kumar D., et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011, 91(2):231-236.
101. Razonable R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011, 86(10):1009-1026.
102. Boivin G., Goyette N., Gilbert C., et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004, 189(9):1615-1618.
103. Razonable R.R., Paya C.V. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003, 10(3):60-65.
104. Bhorade S.M., Lurain N.S., Jordan A., et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant 2002, 21(12):1274-1282.
105. Klintmalm G., Lonnqvist B., Oberg B., et al. Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis 1985, 17(2):157-163.
106. Locke T.J., Odom N.J., Tapson J.S., et al. Successful treatment with trisodium phosphonoformate for primary cytomegalovirus infection after heart transplantation. J Heart Transplant 1987, 6(2):120-122.
107. Mylonakis E., Kallas W.M., Fishman J.A. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002, 34(10):1337-1341.
108. Marschall M., Stamminger T., Urban A., et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012, 56(2):1135-1137.
109. Goldner T., Hewlett G., Ettischer N., et al. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011, 85(20):10884-10893.
110. Kaul D.R., Stoelben S., Cober E., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011, 11(5):1079-1084.
111. Price N.B., Prichard M.N. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011, 1(6):548-554.
112. Avery R.K., Mossad S.B., Poggio E., et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010, 90(4):419-426.
113. Wolf D.G., Shimoni A., Resnick I.B., et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011, 90(3):183-186.
114. Razonable R.R. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2010, 2(1):117-130.
115. Chou S., Marousek G., Bowlin T.L. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother 2012, 56(1):197-201.
116. Avery R.K., Marty F.M., Strasfeld L., et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010, 12(6):489-496.
117. La Rosa C., Longmate J., Lacey S.F., et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis 2012, 205(8):1294-1304.
118. Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377(9773):1256-1263.
119. Manuel O., Husain S., Kumar D., et al. Assessment of cytomegalovirus specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013, 56(6):817-824.
120. Lisboa L.F., Kumar D., Wilson L.E., et al. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012, 93(2):195-200.